Mar Carreño

Mar Carreño

Auto-generated profile, based on publicly available information

Mar Carreño

Epilepsy Unit, Neurology Department Hospital Clínic Barcelona – Member of European Reference Network EpiCARE Barcelona Spain

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2024 in Epilepsia Open
Verified
Journal Article
Open access
MCMar Carreño
Mar Carreño
AGAntonio Gil-Nagel
Antonio Gil-Nagel
JSJosé M. Serratosa
José M. Serratosa
MTManuel Toledo
Manuel Toledo
JRJuan Jesus Rodriguez‐Uranga
Juan Jesus Rodriguez‐Uranga
VVVicente Villanueva
Vicente Villanueva
Objective: Cenobamate is an antiseizure medication (ASM) associated with high rates of seizure freedom and acceptable tolerability in patients with focal seizures. To achieve the optimal cenobamate dose for maximal potential effectiveness while avoiding or minimizing drug‐related adverse events (AEs), the administration of cenobamate with other ASMs must be managed through concomitant ASM load reduction. A panel of Spanish epilepsy experts aimed to provide a Spanish consensus on how to adjust the dose of concomitant ASMs in patients with drug‐resistant epilepsy (DRE) in order to improve the effectiveness and tolerability of adjunctive cenobamate.Methods: A three‐stage modified Delphi consensus process was undertaken, including six Spanish epileptologists with extensive experience using cenobamate. Based on current literature and their own expert opinion, the expert panel reached a consensus on when and how to adjust the dosage of concomitant ASMs during cenobamate titration.Results: The expert panel agreed that tailored titration and close follow‐up are required to achieve the best efficacy and tolerability when initiating cenobamate in patients receiving concomitant ASMs. When concomitant clobazam, phenytoin, phenobarbital, and sodium channel blockers are taken at high dosages, or when the patient is receiving two or more sodium channel blockers, dosages should be proactively lowered during the cenobamate titration period. Other concomitant ASMs should be reduced only if the patient reports a moderate/severe AE at any stage of the titration period.Significance: Cenobamate is an effective ASM with a dose‐dependent effect. To maximize effectiveness while maintaining the best tolerability profile, co‐medication management is needed. The recommendations included herein provide practical guidance for proactive and reactive management of co‐medication in cenobamate‐treated patients with DRE and a high drug load.Plain Language Summary: Patients with epilepsy may continue to have seizures even after treatment with several different antiseizure medications (ASMs). Cenobamate is an ASM that can reduce seizures in these patients. In this study, six Spanish experts in epilepsy discussed the best way to use cenobamate in drug‐resistant epilepsy. They provide practical guidance on when and how the dose of other ASMs might be adjusted to reduce side effects and optimize the use of cenobamate.

1 April 2025 in Epilepsia Open
Verified
Journal Article
Open access
JJJoana Jesus‐Ribeiro
Joana Jesus‐Ribeiro
EREugenia Roza
Eugenia Roza
BOBárbara Oliveiros
Bárbara Oliveiros
JMJoana B. Melo
Joana B. Melo
MCMar Carreño
Mar Carreño
Objective: Artificial intelligence chatbots have been a game changer in healthcare, providing immediate, round‐the‐clock assistance. However, their accuracy across specific medical domains remains under‐evaluated. Dravet syndrome remains one of the most challenging epileptic encephalopathies, with new data continuously emerging in the literature. This study aims to evaluate and compare the performance of ChatGPT 3.5 and Perplexity in responding to questions about Dravet Syndrome.Methods: We curated 96 questions about Dravet syndrome, 43 from healthcare professionals and 53 from caregivers. Two epileptologists independently graded the chatbots' responses, with a third senior epileptologist resolving any disagreements to reach a final consensus. Accuracy and completeness of correct answers were rated on predefined 3‐point scales. Incorrect responses were prompted for self‐correction and re‐evaluated. Readability was assessed using Flesch reading ease and Flesch–Kincaid grade level.Results: Both chatbots had the majority of their responses rated as “correct” (ChatGPT 3.5: 66.7%, Perplexity: 81.3%), with no significant difference in performance between the two (χ2 = 5.30, p = 0.071). ChatGPT 3.5 performed significantly better for caregivers than for healthcare professionals (χ2 = 7.27, p = 0.026). The topic with the poorest performance was Dravet syndrome's treatment, particularly for healthcare professional questions. Both models exhibited exemplary completeness, with most responses rated as “complete” to “comprehensive” (ChatGPT 3.5: 73.4%, Perplexity: 75.7%). Substantial self‐correction capabilities were observed: ChatGPT 3.5 improved 55.6% of responses and Perplexity 80%. The texts were generally very difficult to read, requiring an advanced reading level. However, Perplexity's responses were significantly more readable than ChatGPT 3.5's [Flesch reading ease: 29.0 (SD 13.9) vs. 24.1 (SD 15.0), p = 0.018].Significance: Our findings underscore the potential of AI chatbots in delivering accurate and complete responses to Dravet syndrome queries. However, they have limitations, particularly in complex areas like treatment. Continuous efforts to update information and improve readability are essential.Plain Language Summary: Artificial intelligence chatbots have the potential to improve access to medical information, including on conditions like Dravet syndrome, but the quality of this information is still unclear. In this study, ChatGPT 3.5 and Perplexity correctly answered most questions from healthcare professionals and caregivers, with ChatGPT 3.5 performing better for caregivers. Treatment‐related questions had the most incorrect answers, particularly those from healthcare professionals. Both chatbots demonstrated the ability to correct previous incorrect responses, particularly Perplexity. Both chatbots produced text requiring advanced reading skills. Further improvements are needed to make the text easier to understand and address difficult medical topics.

12 December 2024 in Epilepsia Open
Verified
Journal Article
Open access
AJAleix Jareno‐Badenas
Aleix Jareno‐Badenas
MMMario Matute‐González
Mario Matute‐González
Luis PintorLuis Pintor
Luis Pintor
ECEstefanía Conde‐Blanco
Estefanía Conde‐Blanco
MCMar Carreño
Mar Carreño
SGSofía González-Ortiz
Sofía González-Ortiz
Objective: Psychogenic non‐epileptic seizures (PNES) mimic epileptic seizures without electroencephalographic correlation. Although classified as psychiatric disorders, their neurobiological or structural basis remains unclear. This study aimed to assess the prevalence and characteristics of MRI abnormalities in patients with PNES and those with comorbid epilepsy, compared to the general population, to enhance radiological evaluation and management.Method: We retrospectively identified patients with a definitive diagnosis of PNES, evaluated in the refractory epilepsy unit of our tertiary epilepsy center. Patients were classified into two groups according to their comorbidity with epilepsy (PNES and PNES+). The MRI findings were evaluated and classified by two radiologists, who reported the category of the findings, laterality, and location. The two groups were compared using the chi‐square test, as well as the frequencies of findings in the general population extracted from the literature.Results: Forty‐six patients fulfilled the inclusion criteria. Thirty females and 16 males. MRI findings were present in 25/35 (71.4%) patients in the PNES group and 9/11 (81.8%) In the PNES + group, showing statistically significant differences in the frequency of findings with the general population (8.4–28.1%).Significance: MRI anomalies are common in PNES patients and even more prevalent in complex cases referred to epilepsy units, underscoring the necessity of correlating MRI findings with clinical‐electrical patterns.Plain Language Summary: In this article, we observed a higher frequency of cerebral magnetic resonance findings in patients with psychogenic non‐epileptic seizures than in the general population. We also observed a higher frequency of this pathology among women, as well as right cerebral hemisphere affections. The exposed findings suggest a potential structural basis of this pathology. This hypothesis requires confirmation with larger studies.